A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients With Rheumatoid Arthritis.

Trial Profile

A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Prednisone (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPRA-2
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2015 Results of 12 weeks follow up presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2012 Results reporting fatigue scores presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top